atai Life Sciences Announces First Subject Dosed in the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine)

Saved in:
Bibliographic Details
Published inNASDAQ OMX's News Release Distribution Channel
Format Newsletter
LanguageEnglish
Published New York NASDAQ OMX Corporate Solutions, Inc 13.04.2023
Subjects
Capital expenditures
Clinical trials
Epidemics
Intellectual property
Ketamine
Life sciences
Mental depression
Mental disorders
Mental health care
Neurosciences
Pandemics
Product development
R&D
Regulatory approval
Research & development
Safe harbor
Success
Therapists
Online AccessGet full text

Cover

More Information
Description not available.